@article{536609ecbfca4cd88980a7e9085fb3e6,
title = "Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities",
author = "D. De and A. Kaushik and S. Handa and R. Mahajan and E. Schmidt",
note = "Funding Information: The study was supported in part by structural funds of the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L?beck, for excellent technical assistance with the IgE-specific BP180 and BP230 ELISA. Funding Information: The study was supported in part by structural funds of the Clinical Research Unit (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L{\"u}beck, for excellent technical assistance with the IgE‐specific BP180 and BP230 ELISA. Pemphigoid Diseases ",
year = "2021",
month = jul,
doi = "10.1111/jdv.17229",
language = "English",
volume = "35",
pages = "e469--e472",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
number = "7",
}
